相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Amantadine ER (Gocovri(R)) Significantly Increases ON Time Without Any Dyskinesia: Pooled Analyses From Pivotal Trials in Parkinson's Disease
Robert A. Hauser et al.
FRONTIERS IN NEUROLOGY (2021)
Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson's Disease: A Pooled Analysis of 8 Phase 2b/3 Trials
Robert A. Hauser et al.
JOURNAL OF PARKINSONS DISEASE (2021)
Effects of Gocovri (Amantadine) Extended Release Capsules on Non-Motor Symptoms in Patients with Parkinson's Disease and Dyskinesia
Shyamal H. Mehta et al.
NEUROLOGY AND THERAPY (2021)
Motor complications in Parkinson's disease: 13-year follow-up of the CamPaIGN cohort
Han-Joon Kim et al.
MOVEMENT DISORDERS (2020)
Pharmacologic Treatment of Motor Symptoms Associated with Parkinson Disease
Werner Poewe et al.
NEUROLOGIC CLINICS (2020)
EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinsons Disease
Caroline M. Tanner et al.
JOURNAL OF PARKINSONS DISEASE (2020)
Non-motor symptom burden is strongly correlated to motor complications in patients with Parkinson's disease
D. Santos-Garcia et al.
EUROPEAN JOURNAL OF NEUROLOGY (2020)
Predictors of Response for Off Time Improvement With Levodopa-Carbidopa Intestinal Gel Treatment: An Analysis of the GLORIA Registry
Werner Poewe et al.
FRONTIERS IN NEUROLOGY (2020)
A Pooled Analysis From Phase 2b and 3 Studies in Japan of Istradefylline in Parkinson's Disease
Nobutaka Hattori et al.
MOVEMENT DISORDERS (2020)
Pharmacokinetics of ADS-5102 (Amantadine) ExtendedRelease Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia
Robert A. Hauser et al.
CLINICAL PHARMACOKINETICS (2019)
Minimal clinically important difference for the historic parts of the Unified Dyskinesia Rating Scale
Attila Makkos et al.
PARKINSONISM & RELATED DISORDERS (2019)
Long-term efficacy of opicapone in fluctuating Parkinson's disease patients: a pooled analysis of data from two phase 3 clinical trials and their open-label extensions
J. J. Ferreira et al.
EUROPEAN JOURNAL OF NEUROLOGY (2019)
Prevalence of Dyskinesia and OFF by 30-Minute Intervals Through the Day and Assessment of Daily Episodes of Dyskinesia and OFF: Novel Analyses of Diary Data from Gocovri Pivotal Trials
Robert A. Hauser et al.
JOURNAL OF PARKINSONS DISEASE (2019)
Predictors of motor complications in early Parkinson's disease: A prospective cohort study
Mark J. Kelly et al.
MOVEMENT DISORDERS (2019)
Long-term treatment of Parkinson's disease with levodopa and other adjunctive drugs
Yoshikuni Mizuno et al.
JOURNAL OF NEURAL TRANSMISSION (2018)
Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson's Disease
Lawrence W. Elmer et al.
CNS DRUGS (2018)
Minimal Clinically Important Differences for the Experiences of Daily Living Parts of Movement Disorder Society-Sponsored Unified Parkinson's Disease Rating Scale
Krisztina Horvath et al.
MOVEMENT DISORDERS (2017)
Randomized, Placebo-Controlled Trial of ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson's Disease (EASE LID 3)
Wolfgang Oertel et al.
MOVEMENT DISORDERS (2017)
An updated meta-analysis of amantadine for treating dyskinesia in Parkinson's disease
Min Kong et al.
ONCOTARGET (2017)
Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations A Randomized Clinical Trial
Andrew J. Lees et al.
JAMA NEUROLOGY (2017)
ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study) A Randomized Clinical Trial
Rajesh Pahwa et al.
JAMA NEUROLOGY (2017)
Factors associated with motor complications in Parkinson's disease
Liis Kadastik-Eerme et al.
BRAIN AND BEHAVIOR (2017)
Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial
Joaquim J. Ferreira et al.
LANCET NEUROLOGY (2016)
Trends in inpatient antiparkinson drug use in the USA, 2001-2012
James A. G. Crispo et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial
Robert A. Hauser et al.
LANCET NEUROLOGY (2014)
Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial
Robert A. Hauser et al.
LANCET NEUROLOGY (2013)
Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease
C. Warren Olanow et al.
MOVEMENT DISORDERS (2013)
Determination of Minimal Clinically Important Change in Early and Advanced Parkinson's Disease
Robert A. Hauser et al.
MOVEMENT DISORDERS (2011)
Long-Term Antidyskinetic Efficacy of Amantadine in Parkinson's Disease
Elisabeth Wolf et al.
MOVEMENT DISORDERS (2010)
Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson's disease patients with motor complications
Rebecca Stowe et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2010)
Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale Presentation and Clinimetric Testing Results
Christopher G. Goetz et al.
MOVEMENT DISORDERS (2008)
Advanced Parkinson disease treated with rotigotine transdermal system - PREFER Study
Peter A. LeWitt et al.
NEUROLOGY (2007)
Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease
Robert A. Hauser et al.
ARCHIVES OF NEUROLOGY (2006)
Amantadine for dyskinesia in patients affected by severe Parkinson's disease
C Paci et al.
NEUROLOGICAL SCIENCES (2001)
Continuous dopamine-receptor stimulation in early Parkinson's disease
CW Olanow et al.
TRENDS IN NEUROSCIENCES (2000)
A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia
RA Hauser et al.
CLINICAL NEUROPHARMACOLOGY (2000)
分享论文
